Literature DB >> 21789480

Early activation of interferon-stimulated genes in human liver allografts: relationship with acute rejection and histological outcome.

Rosalba Minisini1, Paola Giarda, Glenda Grossi, Davide Bitetto, Pierluigi Toniutto, Edmondo Falleti, Claudio Avellini, Giuseppa Occhino, Carlo Fabris, Mario Pirisi.   

Abstract

BACKGROUND: Innate immunity mechanisms have been shown to play a paramount role in organ transplantation. Our aim was to investigate the hypothesis that activation of the interferon system may affect clinically relevant outcomes, such as acute rejection and/or early fibrosis progression, after liver transplantation.
METHODS: We studied 71 consecutive recipients (57 males; 25 with hepatitis C) who underwent two per protocol graft biopsies: the first, within 60 days after the transplant operation (median 24) and the second, after 1 year. The mRNA expression for five interferon-stimulated genes (Mx1, OAS2, PKR, IRF7A, IFI16) was measured on the first biopsy specimens. The main outcome measures were acute rejection during the first post-transplant year and fibrosis progression at the second biopsy.
RESULTS: On multivariate analysis, the independent predictors of gene expression were hepatitis C (Mx1, OAS2, PKR and IFI16), donor age (IFI16) and recipient gender (IRF7A) (P < .05 for all). During the first post-transplant year, 19/71 patients (27%) had acute cellular rejection. At multivariate analysis, acute cellular rejection was independently predicted by high IRF7A mRNA expression. At the end of follow-up, 25 patients had some degree of fibrosis (F2 or higher in seven cases). On multivariate analysis, hepatitis C etiology, recipient age, and OAS2 overexpression were independent predictors of early fibrosis progression.
CONCLUSIONS: In the early postoperative period of liver transplantation, interferon-stimulated gene activation is dependent on hepatitis C recurrence (the main factor responsible for early fibrosis progression) and donor age, and is related to the risk of acute cellular rejection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789480     DOI: 10.1007/s00535-011-0440-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  28 in total

1.  Absence of innate MyD88 signaling promotes inducible allograft acceptance.

Authors:  Wendy E Walker; Isam W Nasr; Geoffrey Camirand; Bethany M Tesar; Carmen J Booth; Daniel R Goldstein
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

2.  Rejection under alpha interferon therapy in liver transplant recipients.

Authors:  T Walter; J Dumortier; O Guillaud; V Hervieu; P Paliard; J-Y Scoazec; O Boillot
Journal:  Am J Transplant       Date:  2007-01       Impact factor: 8.086

Review 3.  Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response.

Authors:  Robert H Silverman
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

4.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 5.  Functional classification of interferon-stimulated genes identified using microarrays.

Authors:  M J de Veer; M Holko; M Frevel; E Walker; S Der; J M Paranjape; R H Silverman; B R Williams
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

Review 6.  Modulation of Toll-interleukin 1 receptor mediated signaling.

Authors:  Xiaoxia Li; Jinzhong Qin
Journal:  J Mol Med (Berl)       Date:  2005-01-21       Impact factor: 4.599

7.  IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells.

Authors:  Eun-Joo Kim; Jong-In Park; Barry D Nelkin
Journal:  J Biol Chem       Date:  2004-11-30       Impact factor: 5.157

8.  Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts.

Authors:  Cinzia Borgogna; Pierluigi Toniutto; Carlo Smirne; Barbara Azzimonti; Massimo Rittà; Claudio Avellini; Carlo Fabris; Santo Landolfo; Marisa Gariglio; Mario Pirisi
Journal:  Histopathology       Date:  2009-06       Impact factor: 5.087

9.  Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.

Authors:  Stephen C Rayhill; You Min Wu; Daniel A Katz; Michael D Voigt; Douglas R Labrecque; Patricia A Kirby; Frank A Mitros; Roberto S Kalil; Rachel A Miller; Alan H Stolpen; Warren N Schmidt
Journal:  Transplantation       Date:  2007-08-15       Impact factor: 4.939

10.  Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant.

Authors:  Carmen E Gómez; Andrée Marie Vandermeeren; María Angel García; Elena Domingo-Gil; Mariano Esteban
Journal:  Virol J       Date:  2005-09-12       Impact factor: 4.099

View more
  1 in total

1.  Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function.

Authors:  Pritha Sen; Adrian R Wilkie; Fei Ji; Yiming Yang; Ian J Taylor; Miguel Velazquez-Palafox; Emilia A H Vanni; Jean M Pesola; Rosio Fernandez; Han Chen; Liza M Morsett; Erik R Abels; Mary Piper; Rebekah J Lane; Suzanne E Hickman; Terry K Means; Eric S Rosenberg; Ruslan I Sadreyev; Bo Li; Donald M Coen; Jay A Fishman; Joseph El Khoury
Journal:  Sci Adv       Date:  2020-04-22       Impact factor: 14.957

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.